WO2023180431A1 - Imatinib for use in the treatment of acute respiratory distress syndrome - Google Patents
Imatinib for use in the treatment of acute respiratory distress syndrome Download PDFInfo
- Publication number
- WO2023180431A1 WO2023180431A1 PCT/EP2023/057432 EP2023057432W WO2023180431A1 WO 2023180431 A1 WO2023180431 A1 WO 2023180431A1 EP 2023057432 W EP2023057432 W EP 2023057432W WO 2023180431 A1 WO2023180431 A1 WO 2023180431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imatinib
- treatment
- ards
- patient
- less
- Prior art date
Links
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 239000005517 L01XE01 - Imatinib Substances 0.000 title claims abstract description 75
- 229960002411 imatinib Drugs 0.000 title claims abstract description 75
- 238000011282 treatment Methods 0.000 title claims abstract description 52
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title claims abstract description 47
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 title claims description 42
- 201000000028 adult respiratory distress syndrome Diseases 0.000 title claims description 42
- 102000009027 Albumins Human genes 0.000 claims abstract description 48
- 108010088751 Albumins Proteins 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 13
- 208000025721 COVID-19 Diseases 0.000 claims description 10
- 238000009423 ventilation Methods 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 4
- 206010013647 Drowning Diseases 0.000 claims description 4
- 208000003870 Drug Overdose Diseases 0.000 claims description 4
- 206010033296 Overdoses Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 231100000725 drug overdose Toxicity 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010003504 Aspiration Diseases 0.000 claims description 2
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims description 2
- 238000005399 mechanical ventilation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 241001678559 COVID-19 virus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- -1 at least 2 days Chemical compound 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003374 extravascular lung water Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000027028 long COVID Diseases 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 description 1
- 229940075124 molnupiravir Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- ARDS Respiratory Distress Syndrome
- ARDS is a life-threatening respiratory condition where the lungs cannot provide the body's vital organs with enough oxygen. ARDS happens when the lungs become severely inflamed from an infection or injury. The inflammation causes fluid from nearby blood vessels to leak into the tiny air sacs in your lungs, making breathing increasingly difficult.
- ARDS is a heterogeneous condition resulting from a number of causes including pneumonia (of bacterial, fungal or viral origin -- including COVID-19), sepsis, trauma (for example of the head or chest), aspiration, blood transfusion, pancreatitis, ischemia-reperfusion injury, drug overdose, esophagectomy, drowning or burns.
- ARDS affects over 400,000 patients in the US and Europe per annum. Around 30-40% of the affected patients succumb to the condition and the ones who survive face long- term physical and neuro-psychological conditions effecting their quality of life. The disease has no approved pharmacotherapy and the patient has to rely on prolonged, unreliable and costly ventilatory treatment to manage the symptoms.
- EP2717883 discloses the use of inhibitors of ARG (abl related gene or abl-2 kinase) kinase (such as imatinib) in the treatment of inflammatory oedema, of which ARDS is an example.
- ARG abl related gene or abl-2 kinase
- a first aspect of the present invention is imatinib or a pharmaceutically acceptable salt thereof, for use in the treatment of Acute Respiratory Distress Syndrome (ARDS), wherein the subject of treatment has a blood albumin level of less than 35 g/L.
- a second aspect of the invention provides a use of imatinib or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of Acute Respiratory Distress Syndrome (ARDS), wherein the subject of treatment has a blood albumin level of less than 35 g/L.
- a third aspect of the invention provides a method of treating ARDS comprising administering a patient with imatinib or a pharmaceutically acceptable salt thereof wherein the subject of treatment has a blood albumin level of less than 35 g/L.
- a fourth aspect of the invention provides a method of determining treatment of a patient with ARDS, comprising measuring the blood albumin level of the patient.
- treatment or “treating” as used herein, we refer to therapeutic (curative) treatment including amelioration. Treatment also includes stopping the disease from developing or slowing further progression of the disease. For example, treatment may include preventing symptoms from worsening.
- ARDS is typically diagnosed according to the Berlin criteria (Table 1 below).
- the ARDS is mild, moderate or severe ARDS preferably according to the Berlin criteria, preferably moderate or severe ARDS.
- Table 1 Berlin criteria for diagnosis of ARDS (adapted from Rubenfeld et al. Incidence and outcomes of acute lung injury N Engl J Med 2005, 353, 1685–93) Timing Within 1 week of a known clinical insult or ne / orsenin res irator s m toms .
- r Albumin is a type of protein made in the liver. It is one of the most abundant proteins in human blood. It is well known in the art how to perform a simple and common serum albumin blood test in order to measure a patient’s blood albumin levels (see for instance Chapter 3 in Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition Walker HK, Hall WD, Hurst JW, editors, 1990). In the instance of the present invention, a “low blood albumin level” is considered to be less than 35 g/L. Relative to some of the other biomarkers considered either to classify ARDS, or prognose its treatment, albumin is significantly easier and quicker to measure, providing another benefit to the invention; time is of the essence in an emergency care setting.
- the subject of treatment has a blood albumin level of less than 34 g/L, preferably less than 33.5 g/L, preferably less than 33 g/L, preferably less than 32.5 g/L, more preferably less than 32 g/L, yet more preferably 31.9 g/L, yet more preferably less than 31.5 g/L, even more preferably less than 31 g/L, such as less than 30.5 g/L, for example less than 30 g/L, and/or the subject of treatment has a blood albumin level of more than 20 g/L, preferably more than 22 g/L, more preferably more than 24 g/L, even more preferably more than 26 g/L.
- the subject of treatment has, or is suspected of having, pneumonia of bacterial, fungal or viral origin, a viral infection, sepsis, trauma (for example head or chest trauma), aspiration, blood transfusion, pancreatitis, ischemia-reperfusion injury, drug overdose, esophagectomy, drowning, smoke inhalation, aspiration or burns.
- a viral infection preferably a coronavirus infection, for example SARS (severe acute respiratory syndrome) or SARS-CoV-2, and preferably COVID-19 or long COVID.
- the subject to be treated is infected with, or suspected to be infected with, a coronavirus, such as Covid-19.
- a coronavirus such as Covid-19.
- the subject infected with, or suspected to be infected with, a coronavirus is categorised as stage 3, 4, or 5 on the WHO Ordinal Scale for Clinical Improvement.
- WHO Ordinal Scale for Clinical Improvement measures illness severity over time (Michael O’Kelly & Siying Li (2020), Statistics in Biopharmaceutical Research, 12:4, 451-460).
- “Covid-19” refers to an infectious disease caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Mechanical ventilation is the primary supportive, invasive measure utilized in patients with acute respiratory distress syndrome.
- the subject of treatment has received invasive ventilation, i.e. before the subject receives treatment with imatinib.
- the subject of treatment has received invasive ventilation on at least 1 day within the 7 days prior to receiving imatinib, such as at least 2 days, 3 days, 4 days, 5 days, 6 days or 7 days.
- the subject of treatment has received invasive ventilation on the day before receiving imatinib, and/or the subject of treatment has received invasive ventilation on the same day as receiving imatinib.
- the patient may have days receiving invasive ventilation whilst undergoing treatment with imatinib.
- a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
- Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulfonic, ethanesulfonic, salicylic, stearic, benzenesulfonic or p-toluenesulfonic acid.
- Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aryl amines or heterocyclic amines.
- the compound of the invention may be formulated as a pharmaceutical composition comprising imatinib or a pharmaceutically acceptable salt thereof.
- imatinib is the only active agent in the composition.
- active agent it is meant that the composition does not contain other components which may be used in the treatment of ARDS.
- imatinib may be administered alongside a second active agent for treating ARDS, i.e. the composition comprising imatinib may also comprise a second active agent, or the second active agent may be administered in a separate composition.
- the two compositions are administered to the subject simultaneously, separately or sequentially.
- imatinib may be administered alongside a second active agent for treating an ailment that is not ARDS
- the second active agent may be an active agent that treats pneumonia of bacterial, fungal or viral origin, a viral infection, sepsis, trauma (for example head or chest trauma), aspiration, blood transfusion, pancreatitis, ischemia-reperfusion injury, drug overdose, esophagectomy, drowning or burns.
- the second active agent treats a viral infection, preferably a coronavirus infection, for example SARS (severe acute respiratory syndrome) or SARS-CoV-2, preferably COVID-19.
- the two active agents may be formulated into a single composition, or administered via two separate compositions.
- exemplary second active agents that may be used are anti- viral drugs, such as Remdesivir, Chloroquine, Hydroxychloroquine, Azithromycin, Ivermectin, Lopinavir, Ritonavir, Molnupiravir, Nitazoxanide, baricitinib or tocilizumab, preferably remdesivir or dexamethasone.
- the compositions of the present invention provide for the administration of more than one drug, and they can be administered simultaneously, sequentially or separately. It is not necessary that they are packed together (but this is one embodiment of the invention). It is also not necessary that they are administered at the same time.
- “separate” administration means that the drugs are administered as part of the same overall dosage regimen (which could comprise a number of days), but preferably on the same day.
- “simultaneously” means that the drugs are to be taken together or formulated as a single composition.
- “sequentially” means that the drugs are administered at about the same time, and preferably within about 1 hour of each other.
- the compositions comprising imatinib, or a pharmaceutically acceptable salt thereof may contain a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier is meant any diluent or excipient, such as fillers or binders, that is compatible with the other ingredients of the composition, and which is not deleterious to the recipient.
- the pharmaceutically acceptable carrier can be selected on the basis of the desired route of administration, in accordance with standard pharmaceutical practices.
- imatinib may be administered in a variety of dosage forms.
- imatinib may be formulated in a format suitable for oral, rectal, parenteral, intranasal or transdermal administration or administration by inhalation or by suppository.
- Imatinib may be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
- imatinib is formulated such that it is suitable for oral administration, for example tablets and capsules.
- Imatinib may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. Imatinib may also be administered as suppositories. Imatinib may also be administered by inhalation.
- An advantage of inhaled medications is their direct delivery to the area of rich blood supply in comparison to many medications taken by oral route. Thus, the absorption is very rapid as the alveoli have an enormous surface area and rich blood supply and first pass metabolism is bypassed.
- the present invention also provides an inhalation device containing imatinib. Typically said device is a metered dose inhaler (MDI), which contains a pharmaceutically acceptable chemical propellant to push the medication out of the inhaler.
- MDI metered dose inhaler
- Imatinib may also be administered by intranasal administration.
- the nasal cavity’s highly permeable tissue is very receptive to medication and absorbs it quickly and efficiently.
- Nasal drug delivery is less painful and invasive than injections, generating less anxiety among patients. By this method absorption is very rapid and first pass metabolism is usually bypassed, thus reducing inter-patient variability.
- the present invention also provides an intranasal device containing imatinib.
- Imatinib may also be administered by sublingual administration.
- the present invention therefore also provides a sub-lingual tablet comprising imatinib.
- Imatinib may also be formulated with an agent which reduces degradation of the substance by processes other than the normal metabolism of the patient, such as anti- bacterial agents, or inhibitors of protease enzymes which might be the present in the patient or in commensural or parasite organisms living on or within the patient, and which are capable of degrading the compound.
- Liquid dispersions for oral administration may be syrups, emulsions and suspensions. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g.
- sterile water olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
- Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
- imatinib is administered in an effective amount to treat the symptoms of pneumonitis and/or myocarditis.
- An effective dose will be apparent to one skilled in the art and is dependent on a number of factors including age, sex, weight, which the medical practitioner will be capable of determining.
- imatinib is administered in doses of 0.5 to 400 mg, more preferably 1 to 400 mg, more preferably 2.5 to 400 mg, more preferably 5 mg to 400 mg, more preferably 100 to 500 mg, preferably 200 mg to 450 mg, preferably 300 mg to 400 mg.
- the lower limit for a dose is preferably 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg or 200 mg.
- the upper limit for a dose is preferably 400 mg, 390 mg, 380 mg, 370 mg, 360 mg, 350 mg, 340 mg, 330, mg, 320 mg, 310 mg, 300 mg, 290 mg, 280 mg, 270 mg, 260 mg, 250 mg, 240 mg, 230 mg, 220 mg or 210 mg. Any of the aforementioned lower or upper limits of the ranges may be combined with each other and are herein disclosed.
- the dose is 300 mg to 400 mg.
- the dose is 400 mg. Any of the above doses may be administered once a day or twice a day, preferably twice a day.
- imatinib is administered at least once a day.
- the single daily dose is of 200 mg to 450 mg, preferably 300 mg to 400 mg. Preferably it is 400 mg. It will be appreciated that a lower dose may be needed in a paediatric patient.
- imatinib is administered twice daily. Preferably each dose is 200 mg to 450 mg, preferably 300 mg to 400 mg. Preferably it is 400 mg.
- the dosage regime is such that the total daily dosage of imatinib does not exceed 800 mg, more preferably 400 mg.
- the present invention also relates to use of imatinib, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of ARDS, wherein the subject of treatment has a blood albumin level of less than 35 g/L.
- This embodiment of the invention may have any of the preferred features described above.
- the subject of treatment is or is suspected to having a viral infection, such as a coronavirus infection, for example Covid-19.
- the present invention also relates to a method of treating ARDS comprising administering the patient with Imatinib or a pharmaceutically acceptable salt thereof, wherein the patient has a blood albumin level of less than 35 g/L.
- This embodiment of the invention may have any of the preferred features described above.
- the method of administration may be according to any of the routes described above.
- the patient has a blood albumin level of less than the median level for ARDS patients.
- the present invention also relates to a method of determining treatment of a patient with ARDS, comprising measuring the blood albumin level of the patient.
- patients are found to respond far more positively to imatinib treatment with low amounts of blood albumin levels than patients with high blood albumin levels. Therefore, the present invention allows for more accurate prognosis and decisions to be made by physicians on whether to administer a patient with imatinib.
- This embodiment of the invention may have any of the preferred features described above.
- the measured albumin level is less than 35 g/L, preferably less than 34 g/L, more preferably less than 33 g/L, more preferably less than 32 g/L, yet more preferably 31.9 g/L, even more preferably less than 31 g/L, such as less than 30 g/L and the patient is prescribed imatinib or a pharmaceutically acceptable salt thereof.
- the measured albumin level is 35 g/L or more and the patient is not prescribed imatinib or a pharmaceutically acceptable salt thereof.
- the measured albumin level is more than 20 g/L, preferably more than 22 g/L, more preferably more than 24 g/L, even more preferably more than 26 g/L and the patient is prescribed imatinib or a pharmaceutically acceptable salt thereof.
- the measured albumin level is less than the median level for ARDS patients.
- the measuring of the blood albumin level of the patient is performed in vitro, using any suitable method.
- the present invention also embraces prodrugs which react in vivo to give a compound of the present invention. The following examples illustrate the invention. Examples The CounterCOVID study as reported in Lancet Resp Med. 2021, 9, 957-968 was performed.
- VFDsurv This composite endpoint combines mortality with number of days after successful liberation from invasive mechanical ventilation among survivors, truncated at 28 days (Schoenfeld and Bernard, Crit Care Med 2002, 30, 1772–77).
- the VFD surv value is calculated as the lesser of number of days free of invasive mechanical ventilation, or zero if the patient has died.
- Figures in the columns for albumin at inclusion of the patient into the trial (Alb at start) and for albumin at the start of invasive mechanical ventilation (Alb at MV start) are italicised if above the average for their respective columns.
- Figures in parentheses indicate numbers of patients included in the analysis. Alb at MV 31.9 32 33 34 35 start c t- o cut-offs shown in column headings of albumin in g/L at start of mechanical ventilation.
- Figures in parentheses indicate numbers of patients included in the analysis.
- imatinib has had no effect on the patient. It was also found that there was no difference in the outcome based on the concomitant COVID mediation, e.g. remdesivir or dexamethasone. This demonstrates that imatinib is suited to be an ancillary drug to be used in these patients rather than an alternative drug.
- Statistical analysis A statistical analysis of the VFDsurv scores for the placebo and imatinib treated groups of patients who were hypoalbuminemic relative to a value of 32 g/L at the start of invasive mechanical ventilation indicates the difference between these two datasets being significant with a p value of 0.039 according to a two-tailed t-test.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to imatinib or a pharmaceutically acceptable salt thereof, for use in the treatment of Acute Respiratory Distress Syndrome (ARDS), wherein the subject of treatment has an albumin level of less than 35 g/L.
Description
Treatment Field of the Invention The invention relates to imatinib for new treatment uses. Background of the Invention Acute Respiratory Distress Syndrome (ARDS) is a life-threatening respiratory condition where the lungs cannot provide the body's vital organs with enough oxygen. ARDS happens when the lungs become severely inflamed from an infection or injury. The inflammation causes fluid from nearby blood vessels to leak into the tiny air sacs in your lungs, making breathing increasingly difficult. ARDS is a heterogeneous condition resulting from a number of causes including pneumonia (of bacterial, fungal or viral origin -- including COVID-19), sepsis, trauma (for example of the head or chest), aspiration, blood transfusion, pancreatitis, ischemia-reperfusion injury, drug overdose, esophagectomy, drowning or burns. ARDS affects over 400,000 patients in the US and Europe per annum. Around 30-40% of the affected patients succumb to the condition and the ones who survive face long- term physical and neuro-psychological conditions effecting their quality of life. The disease has no approved pharmacotherapy and the patient has to rely on prolonged, unreliable and costly ventilatory treatment to manage the symptoms. Among those that survive, there is substantial long-term morbidity from deficient respiratory function, mental health problems such as post-traumatic stress and depression, kidney dysfunction that may require dialysis and substantial loss of ability to work long after the patient has been discharged from hospital. Currently, management of ARDS is merely supportive and pharmaceutical development in the field has been frustrated by many late-stage failures: the patient is given intravenous fluids and oxygen supplementation via invasive or non-invasive ventilation, while the underlying cause is treated. In many cases, ARDS patients are placed in an artificial coma and intubated in the Intensive Care Unit (ICU) for an average period of around two weeks. Imatinib is an approved chemotherapy drug for the treatment of cancer. It has the systemic name 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3- yl)pyrimidin-2-yl]amino}phenyl)benzamide and the structure:
apy for ARDS that targets the endothelial barrier dysfunction and targets the extravascular lung water (EVLWi), that is responsible for pulmonary oedema, loss of breath, multiple organ failure and ultimately death. EP2717883 discloses the use of inhibitors of ARG (abl related gene or abl-2 kinase) kinase (such as imatinib) in the treatment of inflammatory oedema, of which ARDS is an example. A Phase II trial (CounterCOVID) published in 2021 explored the hypothesis that imatinib has significant potential to the need for oxygen suppletion amongst hospitalised COVID-19 patients. Despite failing the primary endpoint, the trial did show imatinib was able to significantly protect hospitalised patients with COVID-19 from death, reduce their ICU stay and duration of invasive ventilation (Aman et al, Lancet Resp Med. 2021, 9, 957-968). There is a clear unmet need for treatments of ARDS. The present invention seeks to contribute to solving this problem. Summary of the Invention As shown by the data in the Examples section, it has been surprisingly found in clinical trials that blood albumin levels have an impact on the treatment of ARDS with imatinib. With low blood albumin levels, surprisingly, patients respond far more positively to treatment with imitanib than those with high levels. Thus, a first aspect of the present invention is imatinib or a pharmaceutically acceptable salt thereof, for use in the treatment of Acute Respiratory Distress Syndrome (ARDS), wherein the subject of treatment has a blood albumin level of less than 35 g/L. A second aspect of the invention provides a use of imatinib or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of Acute Respiratory Distress Syndrome (ARDS), wherein the subject of treatment has a blood albumin level of less than 35 g/L.
A third aspect of the invention provides a method of treating ARDS comprising administering a patient with imatinib or a pharmaceutically acceptable salt thereof wherein the subject of treatment has a blood albumin level of less than 35 g/L. A fourth aspect of the invention provides a method of determining treatment of a patient with ARDS, comprising measuring the blood albumin level of the patient. Detailed Description of the Invention By the term “treatment” or “treating” as used herein, we refer to therapeutic (curative) treatment including amelioration. Treatment also includes stopping the disease from developing or slowing further progression of the disease. For example, treatment may include preventing symptoms from worsening. “Amelioration” is an improvement, or perceived improvement, in the patient’s condition, or a change in a patient’s condition that makes it, or side-effects, increasingly tolerable. ARDS is typically diagnosed according to the Berlin criteria (Table 1 below). Suitably in the present invention, the ARDS is mild, moderate or severe ARDS preferably according to the Berlin criteria, preferably moderate or severe ARDS. Table 1 Berlin criteria for diagnosis of ARDS (adapted from Rubenfeld et al. Incidence and outcomes of acute lung injury N Engl J Med 2005, 353, 1685–93) Timing Within 1 week of a known clinical insult or ne / orsenin res irator s m toms . ) r
Albumin is a type of protein made in the liver. It is one of the most abundant proteins in human blood. It is well known in the art how to perform a simple and common serum albumin blood test in order to measure a patient’s blood albumin levels (see for instance Chapter 3 in Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition Walker HK, Hall WD, Hurst JW, editors, 1990). In the instance of the present invention, a “low blood albumin level” is considered to be less than 35 g/L. Relative to some of the other biomarkers considered either to classify ARDS, or prognose its treatment, albumin is significantly easier and quicker to measure, providing another benefit to the invention; time is of the essence in an emergency care setting. However, before the present invention, there was no knowledge that ARDS patients could be better treated with imatinib by reference to their albumin levels. This finding is new and unexpected. Suitably the subject of treatment has a blood albumin level of less than 34 g/L, preferably less than 33.5 g/L, preferably less than 33 g/L, preferably less than 32.5 g/L, more preferably less than 32 g/L, yet more preferably 31.9 g/L, yet more preferably less than 31.5 g/L, even more preferably less than 31 g/L, such as less than 30.5 g/L, for example less than 30 g/L, and/or the subject of treatment has a blood albumin level of more than 20 g/L, preferably more than 22 g/L, more preferably more than 24 g/L, even more preferably more than 26 g/L. ARDS is often present in patients with other ailments. Thus, in one embodiment the subject of treatment has, or is suspected of having, pneumonia of bacterial, fungal or viral origin, a viral infection, sepsis, trauma (for example head or chest trauma), aspiration, blood transfusion, pancreatitis, ischemia-reperfusion injury, drug overdose, esophagectomy, drowning, smoke inhalation, aspiration or burns. Preferably the subject of treatment has, or is suspected of having, a viral infection, preferably a coronavirus infection, for example SARS (severe acute respiratory syndrome) or SARS-CoV-2, and preferably COVID-19 or long COVID. In one embodiment, the subject to be treated is infected with, or suspected to be infected with, a coronavirus, such as Covid-19. In a further embodiment, the subject infected with, or suspected to be infected with, a coronavirus is categorised as stage 3, 4, or 5 on the WHO Ordinal Scale for Clinical Improvement. WHO Ordinal Scale for
Clinical Improvement measures illness severity over time (Michael O’Kelly & Siying Li (2020), Statistics in Biopharmaceutical Research, 12:4, 451-460). “Covid-19” refers to an infectious disease caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Mechanical ventilation is the primary supportive, invasive measure utilized in patients with acute respiratory distress syndrome. Suitably the subject of treatment has received invasive ventilation, i.e. before the subject receives treatment with imatinib. Preferably the subject of treatment has received invasive ventilation on at least 1 day within the 7 days prior to receiving imatinib, such as at least 2 days, 3 days, 4 days, 5 days, 6 days or 7 days. Suitably the subject of treatment has received invasive ventilation on the day before receiving imatinib, and/or the subject of treatment has received invasive ventilation on the same day as receiving imatinib. Suitably as imatinib treatment starts and progresses, the patient may have days receiving invasive ventilation whilst undergoing treatment with imatinib. “Patient” and “subject” are used interchangeably and refer to the subject that is to be administered the imatinib. Preferably, the subject is a human. As used herein, a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulfonic, ethanesulfonic, salicylic, stearic, benzenesulfonic or p-toluenesulfonic acid. Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aryl amines or heterocyclic amines. The skilled practitioner would understand that the compound of the invention may be formulated as a pharmaceutical composition comprising imatinib or a pharmaceutically acceptable salt thereof. In one embodiment, imatinib is the only active agent in the composition. By only active agent it is meant that the composition does not contain other components which may be used in the treatment of ARDS. Alternatively, imatinib may be administered alongside a second active agent for treating ARDS, i.e. the composition comprising imatinib may also comprise a second active agent, or the second active agent may be administered in a separate composition. The two
compositions are administered to the subject simultaneously, separately or sequentially. In another embodiment, imatinib may be administered alongside a second active agent for treating an ailment that is not ARDS, for example the second active agent may be an active agent that treats pneumonia of bacterial, fungal or viral origin, a viral infection, sepsis, trauma (for example head or chest trauma), aspiration, blood transfusion, pancreatitis, ischemia-reperfusion injury, drug overdose, esophagectomy, drowning or burns. Preferably the second active agent treats a viral infection, preferably a coronavirus infection, for example SARS (severe acute respiratory syndrome) or SARS-CoV-2, preferably COVID-19. The two active agents may be formulated into a single composition, or administered via two separate compositions. The two compositions are administered to the subject simultaneously, separately or sequentially. Accordingly, exemplary second active agents that may be used are anti- viral drugs, such as Remdesivir, Chloroquine, Hydroxychloroquine, Azithromycin, Ivermectin, Lopinavir, Ritonavir, Molnupiravir, Nitazoxanide, baricitinib or tocilizumab, preferably remdesivir or dexamethasone. The compositions of the present invention provide for the administration of more than one drug, and they can be administered simultaneously, sequentially or separately. It is not necessary that they are packed together (but this is one embodiment of the invention). It is also not necessary that they are administered at the same time. As used herein, “separate” administration means that the drugs are administered as part of the same overall dosage regimen (which could comprise a number of days), but preferably on the same day. As used herein “simultaneously” means that the drugs are to be taken together or formulated as a single composition. As used herein, “sequentially” means that the drugs are administered at about the same time, and preferably within about 1 hour of each other. The compositions comprising imatinib, or a pharmaceutically acceptable salt thereof, may contain a pharmaceutically acceptable carrier. By “pharmaceutically acceptable carrier” is meant any diluent or excipient, such as fillers or binders, that is compatible with the other ingredients of the composition, and which is not deleterious to the recipient. The pharmaceutically acceptable carrier can be selected on the basis of the desired route of administration, in accordance with standard pharmaceutical practices. In the present invention, imatinib may be administered in a variety of dosage forms. In one embodiment, imatinib may be formulated in a format suitable for oral, rectal,
parenteral, intranasal or transdermal administration or administration by inhalation or by suppository. Imatinib may be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. Preferably, imatinib is formulated such that it is suitable for oral administration, for example tablets and capsules. Imatinib may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. Imatinib may also be administered as suppositories. Imatinib may also be administered by inhalation. An advantage of inhaled medications is their direct delivery to the area of rich blood supply in comparison to many medications taken by oral route. Thus, the absorption is very rapid as the alveoli have an enormous surface area and rich blood supply and first pass metabolism is bypassed. The present invention also provides an inhalation device containing imatinib. Typically said device is a metered dose inhaler (MDI), which contains a pharmaceutically acceptable chemical propellant to push the medication out of the inhaler. Imatinib may also be administered by intranasal administration. The nasal cavity’s highly permeable tissue is very receptive to medication and absorbs it quickly and efficiently. Nasal drug delivery is less painful and invasive than injections, generating less anxiety among patients. By this method absorption is very rapid and first pass metabolism is usually bypassed, thus reducing inter-patient variability. Further, the present invention also provides an intranasal device containing imatinib. Imatinib may also be administered by sublingual administration. The present invention therefore also provides a sub-lingual tablet comprising imatinib. Imatinib may also be formulated with an agent which reduces degradation of the substance by processes other than the normal metabolism of the patient, such as anti- bacterial agents, or inhibitors of protease enzymes which might be the present in the patient or in commensural or parasite organisms living on or within the patient, and which are capable of degrading the compound. Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride. Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. In an embodiment of the invention, imatinib is administered in an effective amount to treat the symptoms of pneumonitis and/or myocarditis. An effective dose will be apparent to one skilled in the art and is dependent on a number of factors including age, sex, weight, which the medical practitioner will be capable of determining. In a preferred embodiment, imatinib is administered in doses of 0.5 to 400 mg, more preferably 1 to 400 mg, more preferably 2.5 to 400 mg, more preferably 5 mg to 400 mg, more preferably 100 to 500 mg, preferably 200 mg to 450 mg, preferably 300 mg to 400 mg. The lower limit for a dose is preferably 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg or 200 mg. The upper limit for a dose is preferably 400 mg, 390 mg, 380 mg, 370 mg, 360 mg, 350 mg, 340 mg, 330, mg, 320 mg, 310 mg, 300 mg, 290 mg, 280 mg, 270 mg, 260 mg, 250 mg, 240 mg, 230 mg, 220 mg or 210 mg. Any of the aforementioned lower or upper limits of the ranges may be combined with each other and are herein disclosed. In some embodiments, the dose is 300 mg to 400 mg. In some embodiments, the dose is 400 mg. Any of the above doses may be administered once a day or twice a day, preferably twice a day. In an embodiment of the invention, imatinib is administered at least once a day. Preferably it is administered as a single daily dose. Preferably the single daily dose is of 200 mg to 450 mg, preferably 300 mg to 400 mg. Preferably it is 400 mg. It will be appreciated that a lower dose may be needed in a paediatric patient.
In an embodiment of the invention, imatinib is administered twice daily. Preferably each dose is 200 mg to 450 mg, preferably 300 mg to 400 mg. Preferably it is 400 mg. Preferably, the dosage regime is such that the total daily dosage of imatinib does not exceed 800 mg, more preferably 400 mg. The present invention also relates to use of imatinib, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of ARDS, wherein the subject of treatment has a blood albumin level of less than 35 g/L. This embodiment of the invention may have any of the preferred features described above. In one embodiment, the subject of treatment is or is suspected to having a viral infection, such as a coronavirus infection, for example Covid-19. The present invention also relates to a method of treating ARDS comprising administering the patient with Imatinib or a pharmaceutically acceptable salt thereof, wherein the patient has a blood albumin level of less than 35 g/L. This embodiment of the invention may have any of the preferred features described above. The method of administration may be according to any of the routes described above. In one aspect, the patient has a blood albumin level of less than the median level for ARDS patients. The present invention also relates to a method of determining treatment of a patient with ARDS, comprising measuring the blood albumin level of the patient. In accordance with the invention, patients are found to respond far more positively to imatinib treatment with low amounts of blood albumin levels than patients with high blood albumin levels. Therefore, the present invention allows for more accurate prognosis and decisions to be made by physicians on whether to administer a patient with imatinib. This embodiment of the invention may have any of the preferred features described above. Suitably the measured albumin level is less than 35 g/L, preferably less than 34 g/L, more preferably less than 33 g/L, more preferably less than 32 g/L, yet more preferably 31.9 g/L, even more preferably less than 31 g/L, such as less than 30 g/L and the patient is prescribed imatinib or a pharmaceutically acceptable salt thereof.
Suitably the measured albumin level is 35 g/L or more and the patient is not prescribed imatinib or a pharmaceutically acceptable salt thereof. Suitably the measured albumin level is more than 20 g/L, preferably more than 22 g/L, more preferably more than 24 g/L, even more preferably more than 26 g/L and the patient is prescribed imatinib or a pharmaceutically acceptable salt thereof. In one aspect, the measured albumin level is less than the median level for ARDS patients. Suitably the measuring of the blood albumin level of the patient is performed in vitro, using any suitable method. For the avoidance of doubt, the present invention also embraces prodrugs which react in vivo to give a compound of the present invention. The following examples illustrate the invention. Examples The CounterCOVID study as reported in Lancet Resp Med. 2021, 9, 957-968 was performed. Patients were being administered with standard of care for COVID according to the treating physician’s judgment. That included remdesivir or dexamethasone. Data on albumin levels at study inclusion and at days 1, 3, 5, 7 and 9 were analysed with respect to patient outcome amongst the subset of patients that received invasively mechanical ventilation. This subset includes the patients in the trial who can be considered to have moderate to severe ARDS according to the Berlin criteria. The albumin level used for the analysis is the one closest in time to the start of invasive mechanical ventilation. Albumin values are given in g/L. Group A is placebo group; Group B is imatinib treated with a loading dose of 800 mg at the start of the trial followed by a daily dose of 400 mg for a further 9 days (10 days total dosing). Patients were monitored for 28 days. Treatment effect is measured using the number of ventilator-free days while alive at Day 28, which is the most widely used composite outcome in the ARDS literature (VFDsurv). This composite endpoint combines
mortality with number of days after successful liberation from invasive mechanical ventilation among survivors, truncated at 28 days (Schoenfeld and Bernard, Crit Care Med 2002, 30, 1772–77). The VFDsurv value is calculated as the lesser of number of days free of invasive mechanical ventilation, or zero if the patient has died. Figures in the columns for albumin at inclusion of the patient into the trial (Alb at start) and for albumin at the start of invasive mechanical ventilation (Alb at MV start) are italicised if above the average for their respective columns. The average and standard deviations for the respective columns are shown at the bottom of the tables. An asterisk in the days of mechanical ventilation (days_MV) column indicates death Table 2 Albumin levels and ventilation outcomes from CounterCOVID study of patients with ARDS due to COVID-19 Group Alb at Alb at MV date_start date_stop days_MV VFDsurv start start mv mv
A 32 32 0 24 24 4 B 37.8 30 3 7 4 24
Study participants were then categorised as hypoalbuminemic or hyperalbuminemic with respect to various experimental analytical cut-offs in level of blood albumin at the start of mechanical ventilation from 31g/L to 35g/L. (The median level for the mechanically ventilated population of ARDS patients in the CounterCOVID trial at the time of starting mechanical ventilation was 31.9g/L, whereas the median level of this population at the time of entry into the trial was 35.0g/L.) The VFDsurv value was then analysed for each group.
Table 3: VFDsurv results for patients hypoalbuminemic to cut-offs shown in the column headings of albumin in g/L at start of mechanical ventilation. Figures in parentheses indicate numbers of patients included in the analysis. Alb at MV 31.9 32 33 34 35 start c t-
o cut-offs shown in column headings of albumin in g/L at start of mechanical ventilation. Figures in parentheses indicate numbers of patients included in the analysis. Alb at MV 31.9 32 33 34 35 start c t-
, atients are segregated into responders and non-responders by applying the cut-off of blood albumin level at above the medium value of 31.9 g/L up to 35 g/L. At these levels, the test allocates almost all of the responders into the hypoalbuminemic category and almost all of the non- responders into the hyperalbuminemic category, i.e. table 3 versus table 4 shows that for each albumin blood level, in table 3 (i.e. hypoalbuminemic) there is a great increase in VFDsurv score for patients being treated with imatinib, whereas in table 4 (i.e. hyperalbuminemic) the VFDsurv scores are similar – i.e. imatinib has had no effect on the patient. It was also found that there was no difference in the outcome based on the concomitant COVID mediation, e.g. remdesivir or dexamethasone. This demonstrates that imatinib is suited to be an ancillary drug to be used in these patients rather than an alternative drug. Statistical analysis
A statistical analysis of the VFDsurv scores for the placebo and imatinib treated groups of patients who were hypoalbuminemic relative to a value of 32 g/L at the start of invasive mechanical ventilation indicates the difference between these two datasets being significant with a p value of 0.039 according to a two-tailed t-test. Similar results were found when performed on the results for 31.9 g/L, 33 g/L, 34 g/L and 35 g/L, supporting the statistical difference for each. t-Test: Two-Sample Assuming Unequal Variances Variable Variable 1 2 Mean 8 16.07 Variance 100.62 91.61 Observations 14 14 Hypothesized Mean Difference 0 df 26 t Stat -2.18 P(T<=t) one-tail 0.019 t Critical one-tail 1.71 P(T<=t) two-tail 0.039 t Critical two-tail 2.06 Conclusion The data and analysis supports the conclusion that patients with low blood albumin level will respond far more positively to imitanib treatment of ARDS, than patients with high blood albumin level.
Claims
Claims 1. Imatinib or a pharmaceutically acceptable salt thereof, for use in the treatment of Acute Respiratory Distress Syndrome (ARDS), wherein the subject of treatment has an albumin level of less than 35 g/L.
2. Imatinib for use according to claim 1, wherein the subject of treatment has, or is suspected of having, pneumonia of bacterial, fungal or viral origin, a viral infection, sepsis, trauma (for example head or chest trauma), aspiration, blood transfusion, pancreatitis, ischemia-reperfusion injury, drug overdose, esophagectomy, drowning, smoke inhalation, aspiration or burns.
3. Imatinib for use according to either claim 1 or 2 wherein the subject of treatment has, or is suspected of having, a viral infection, preferably a coronavirus infection, such as COVID-19.
4. Imatinib for use according to any preceding claim wherein the subject of treatment is human.
5. Imatinib for use according to any preceding claim wherein the subject of treatment has an albumin level of less than 34 g/L, preferably less than 33 g/L, more preferably less than 32 g/L, yet more preferably 31.9 g/L, even more preferably less than 31 g/L, such as less than 30 g/L.
6. Imatinib for use according to any preceding claim wherein the subject of treatment has an albumin level of more than 20 g/L, preferably more than 22 g/L, more preferably more than 24 g/L, even more preferably more than 26 g/L.
7. Imatinib for use according to any preceding claim wherein the subject of treatment has received invasive ventilation.
8. Imatinib for use according to any preceding claim wherein the ARDS is moderate or severe ARDS preferably according to the Berlin criteria.
9. Imatinib for use according to any preceding claim, wherein the dose of imatinib is 100 to 500 mg, preferably 200 mg to 450 mg, preferably 300 mg to 400 mg, most preferably about 400 mg.
10. Imatinib for use according to any preceding claim, wherein the dose is administered once per day.
11. Imatinib for use according to any one of claims 1 to 9, wherein the dose is administered twice per day.
12. Imatinib for use according to any preceding claim, to be administered intravenously or orally, preferably orally.
13. Imatinib for use according to any of claims 1 to 11, to be administered by parenteral, transdermal, sublingual, rectal or inhaled administration.
14. Use of Imatinib, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of ARDS, wherein the subject of treatment has a an albumin level of less than 35 g/L.
15. The use of Imatinib, or a pharmaceutically acceptable salt thereof, according to claim 14 having any of the additional features of claims 2 to 13.
16. A method of treating ARDS comprising administering the patient with imatinib or a pharmaceutically acceptable salt thereof, wherein the patient has an albumin level of less than 35 g/L.
17. A method of treating ARDS comprising administering the patient with imatinib or a pharmaceutically acceptable salt thereof, wherein the patient has an albumin level of less than the median level for ARDS patients.
18. The method according to claim 16 or 17 having any of the additional features of claims 2 to 13.
19. A method of determining treatment of a patient with ARDS, comprising measuring the blood albumin level of the patient.
20. The method according to claim 19 wherein the measured albumin level is of less than 35 g/L and the patient is prescribed imatinib or a pharmaceutically acceptable salt thereof.
21. The method according to claim 19 wherein the measured albumin level is 35 g/L or more and the patient is not prescribed imatinib or a pharmaceutically acceptable salt thereof.
22. The method according to claim 19 wherein the patient has an albumin level of less than the median level for ARDS patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2204070.3 | 2022-03-23 | ||
GBGB2204070.3A GB202204070D0 (en) | 2022-03-23 | 2022-03-23 | Treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023180431A1 true WO2023180431A1 (en) | 2023-09-28 |
Family
ID=81344807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/057432 WO2023180431A1 (en) | 2022-03-23 | 2023-03-23 | Imatinib for use in the treatment of acute respiratory distress syndrome |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202204070D0 (en) |
WO (1) | WO2023180431A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012150857A1 (en) * | 2011-05-02 | 2012-11-08 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
-
2022
- 2022-03-23 GB GBGB2204070.3A patent/GB202204070D0/en not_active Ceased
-
2023
- 2023-03-23 WO PCT/EP2023/057432 patent/WO2023180431A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012150857A1 (en) * | 2011-05-02 | 2012-11-08 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
EP2717883A1 (en) | 2011-05-02 | 2014-04-16 | Vereniging Voor Christelijk Hoger Onderwijs, Weten | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
Non-Patent Citations (5)
Title |
---|
"Clinical Methods: The History, Physical, and Laboratory Examinations", 1990 |
AMAN ET AL., LANCET RESP MED., vol. 9, 2021, pages 957 - 968 |
AMAN JURJAN ET AL: "Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial", THE LANCET. RESPIRATORY MEDICINE, 17 June 2021 (2021-06-17), Oxford, pages 1 - 12, XP055826369, ISSN: 2213-2600, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S221326002100237X?via%3Dihub> DOI: 10.1016/S2213-2600(21)00237-X * |
ANONYMOUS: "A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care. (IMPRESS COVID)", CLINICALTRIALS.GOV, 29 June 2021 (2021-06-29), INTERNET, pages 1 - 9, XP093045893, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT04953052> [retrieved on 20230510] * |
SCHOENFELDBERNARD, CRIT CARE MED, vol. 30, 2002, pages 1772 - 77 |
Also Published As
Publication number | Publication date |
---|---|
GB202204070D0 (en) | 2022-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11364227B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection | |
JP2011529078A (en) | Methods and compositions for treating and preventing autoimmune diseases | |
US20230128032A1 (en) | Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death | |
WO2023180431A1 (en) | Imatinib for use in the treatment of acute respiratory distress syndrome | |
Alfano et al. | Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19 | |
US20230233576A1 (en) | Eclitasertib for use in treating conditions involving systemic hyperinflammatory response | |
KR20230005157A (en) | AZD1656 for use in the treatment of pneumonia and/or myocarditis due to coronavirus | |
US20230026808A1 (en) | Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury | |
US11471448B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia | |
TWI752756B (en) | Use of ubiquitin-like inhibitor for preparing medicine for preventing, slowing down, improving or treating lung injury caused by breathing apparatus | |
Weng et al. | Artemether ameliorates adriamycin induced cardiac atrophy in mice | |
CN116761620A (en) | Recombinant alkaline phosphatase for the treatment of acute respiratory distress syndrome | |
Zein-Elabdeen et al. | Albuterol as an adjuvant in acute anticholinesterase pesticide poisoning: a randomized, placebo-controlled clinical trial | |
Liao et al. | Yong Qing Liao, Jia Min*, Zheng Xia Wu and Zhi Hu | |
Liu et al. | Clinical efficacy of corticosteroids in the early stage of worsening of COVID-19 pneumonia | |
WO2023041927A1 (en) | Azd1656 for use in the treatment of pneumonitis or myocarditis | |
Alfano et al. | Le Infezioni in Medicina, n. 1, 11-21, 2022 | |
WO2023022616A1 (en) | Method of preventing or treating coronavirus infection | |
CA3190684A1 (en) | Recombinant alkaline phosphatase for use in treating acute respiratory distress syndrome | |
CN117860897A (en) | Application of HCK inhibitor in preparation of medicines for treating pulmonary fibrosis | |
CN113876780A (en) | Pharmaceutical composition and application thereof in preparation of medicines for treating non-small cell lung cancer | |
WARING | Beta-adrenoceptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23715433 Country of ref document: EP Kind code of ref document: A1 |